Novel insights into immune checkpoints in psoriasis and atopic dermatitis: From expression and function to treatments.

IF 4.8 2区医学 Q2 IMMUNOLOGY International immunopharmacology Pub Date : 2024-09-30 Epub Date: 2024-07-29 DOI:10.1016/j.intimp.2024.112663

Hua Liu, Geng Wang, Xinyue Liu, Yan Ren, Yixuan Wang, Jianing Li, Rou Zheng, Xiao Wu, Yanru Zhang, Na Li

{"title":"Novel insights into immune checkpoints in psoriasis and atopic dermatitis: From expression and function to treatments.","authors":"Hua Liu, Geng Wang, Xinyue Liu, Yan Ren, Yixuan Wang, Jianing Li, Rou Zheng, Xiao Wu, Yanru Zhang, Na Li","doi":"10.1016/j.intimp.2024.112663","DOIUrl":null,"url":null,"abstract":"<p><p>Psoriasis and atopic dermatitis (AD) are both chronic inflammatory skin diseases, which are common and difficult to cure. Currently, the emerging biologics have demonstrated outstanding efficacy, but not all patients are able to benefit from them, and traditional systemic treatments come with many severe side effects. The emergence of immune checkpoints brings new hope to solve this problem. Immune checkpoints regulate T cell activation. Upon damage to the co-inhibitory molecules, the inhibition on T cells is removed, leading to the excessive activation of T cells. In this review, we delineate and highlight the expression and function of immune checkpoint molecules (CTLA-4, PD-1, TIM-3, TIGIT, VISTA, LAG-3, OX40, GITR) in psoriasis and AD. We provide preclinical and clinical studies supporting a potential therapeutic approach of targeting these checkpoints for inflammatory skin diseases. Moreover, the complexity of immune checkpoints and safety of clinical application are discussed.</p>","PeriodicalId":13859,"journal":{"name":"International immunopharmacology","volume":null,"pages":null},"PeriodicalIF":4.8000,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International immunopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.intimp.2024.112663","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/29 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Psoriasis and atopic dermatitis (AD) are both chronic inflammatory skin diseases, which are common and difficult to cure. Currently, the emerging biologics have demonstrated outstanding efficacy, but not all patients are able to benefit from them, and traditional systemic treatments come with many severe side effects. The emergence of immune checkpoints brings new hope to solve this problem. Immune checkpoints regulate T cell activation. Upon damage to the co-inhibitory molecules, the inhibition on T cells is removed, leading to the excessive activation of T cells. In this review, we delineate and highlight the expression and function of immune checkpoint molecules (CTLA-4, PD-1, TIM-3, TIGIT, VISTA, LAG-3, OX40, GITR) in psoriasis and AD. We provide preclinical and clinical studies supporting a potential therapeutic approach of targeting these checkpoints for inflammatory skin diseases. Moreover, the complexity of immune checkpoints and safety of clinical application are discussed.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

银屑病和特应性皮炎免疫检查点的新发现：从表达和功能到治疗

银屑病和特应性皮炎（AD）都是慢性炎症性皮肤病，既常见又难以治愈。目前，新兴的生物制剂已显示出卓越的疗效，但并非所有患者都能从中获益，而且传统的全身治疗方法会产生许多严重的副作用。免疫检查点的出现为解决这一问题带来了新希望。免疫检查点能调节 T 细胞的活化。一旦共抑制分子受到破坏，对T细胞的抑制作用就会被解除，从而导致T细胞过度活化。在这篇综述中，我们阐述并强调了免疫检查点分子（CTLA-4、PD-1、TIM-3、TIGIT、VISTA、LAG-3、OX40、GITR）在银屑病和 AD 中的表达和功能。我们提供的临床前和临床研究支持了针对这些检查点治疗炎症性皮肤病的潜在治疗方法。此外，我们还讨论了免疫检查点的复杂性和临床应用的安全性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

International immunopharmacology 医学-免疫学

CiteScore

8.40

自引率

3.60%

发文量

935

审稿时长

53 days

期刊介绍： International Immunopharmacology is the primary vehicle for the publication of original research papers pertinent to the overlapping areas of immunology, pharmacology, cytokine biology, immunotherapy, immunopathology and immunotoxicology. Review articles that encompass these subjects are also welcome. The subject material appropriate for submission includes: • Clinical studies employing immunotherapy of any type including the use of: bacterial and chemical agents; thymic hormones, interferon, lymphokines, etc., in transplantation and diseases such as cancer, immunodeficiency, chronic infection and allergic, inflammatory or autoimmune disorders. • Studies on the mechanisms of action of these agents for specific parameters of immune competence as well as the overall clinical state. • Pre-clinical animal studies and in vitro studies on mechanisms of action with immunopotentiators, immunomodulators, immunoadjuvants and other pharmacological agents active on cells participating in immune or allergic responses. • Pharmacological compounds, microbial products and toxicological agents that affect the lymphoid system, and their mechanisms of action. • Agents that activate genes or modify transcription and translation within the immune response. • Substances activated, generated, or released through immunologic or related pathways that are pharmacologically active. • Production, function and regulation of cytokines and their receptors. • Classical pharmacological studies on the effects of chemokines and bioactive factors released during immunological reactions.